Arcutis Biotherapeutics, Inc.
ARQT
株式のランク
#3954
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
株価
$32.83
時価総額
$4.13B
変化（1日）
2.93%
変化（1年）
57.21%
国
US
取引 Arcutis Biotherapeutics, Inc. (ARQT)
カテゴリー
Healthcare
Arcutis Biotherapeutics, Inc.（ARQT）のP/B比率
October 2026 時点のP/B比率 TTM: 15.63
Arcutis Biotherapeutics, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 15.63 です。2023 年末時点でのP/B比率は 2.52 でした。
Arcutis Biotherapeutics, Inc. の P/B 比率の履歴（2017 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 15.63 | 46.05% |
| 2024 | 10.70 | 323.63% |
| 2023 | 2.52 | -35.03% |
| 2022 | 3.89 | 12.90% |
| 2021 | 3.44 | -7.15% |
| 2020 | 3.71 | -129.04% |
| 2019 | -12.77 | -61.23% |
| 2018 | -32.93 | 614.27% |
| 2017 | -4.61 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -60.00% |
US
|
|
| 13.2547 | -15.18% |
US
|
|
| 4.208 | -73.07% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.44% |
NL
|
